Fresh Tracks Therapeutics, Inc.
NASDAQ: FRTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Albert Nicholas Marchio II
- Employees
- 4
- Headquarters
- Boulder, United States
- IPO year
- 1993
- Market cap
- $5.6M
- Website
- https://www.frtx.com
Loading FRTX…
Loading profile data…Frequently asked questions about FRTX
What does Fresh Tracks Therapeutics, Inc. (FRTX) do?
Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical firm focused on creating diverse prescription therapies to address a range of severe autoimmune, inflammatory, and other chronic debilitating conditions, primarily within the U.S. market. A key compound in its development pipeline is sofpironium bromide, which has successfully co...
Where does FRTX trade?
Fresh Tracks Therapeutics, Inc. (FRTX) trades on the NASDAQ Capital Market.
What sector is FRTX in?
Fresh Tracks Therapeutics, Inc. (FRTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Fresh Tracks Therapeutics, Inc.?
Albert Nicholas Marchio II is the chief executive officer of Fresh Tracks Therapeutics, Inc. (FRTX).
Where is Fresh Tracks Therapeutics, Inc. headquartered?
Fresh Tracks Therapeutics, Inc. is headquartered in United States.
Does FRTX pay a dividend?
Fresh Tracks Therapeutics, Inc. (FRTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did FRTX go public?
Fresh Tracks Therapeutics, Inc. (FRTX) completed its initial public offering in 1993.